Results 1 to 10 of about 45,148 (166)
Post-marketing safety surveillance of Haemophilus influenzae Type b conjugate vaccine in children aged 3 months to 5 years in Jiangsu, China [PDF]
Human Vaccines & ImmunotherapeuticsThis study evaluates the post-marketing safety profile of a Haemophilus influenzae Type b (Hib) conjugate vaccine in children aged 3 months to 5 y in China.
Yuxuan Zhou +5 more
doaj +2 more sources
Development of MenFive®, an affordable pentavalent meningococcal conjugate vaccine (ACYWX) for Africa and beyond [PDF]
Human Vaccines & ImmunotherapeuticsWide use of the groundbreaking vaccine MenAfriVac® has eliminated serogroup A meningococcal meningitis in the African meningitis belt and paved the way for elimination of all meningococcal disease outbreaks with the development, licensure, and ...
Mark R. Alderson +7 more
doaj +2 more sources
Scientific Reports, 2021 Conjugate vaccine platform is a promising strategy to overcome the poor immunogenicity of bacterial polysaccharide antigens in infants and children. A carrier protein in conjugate vaccines works not only as an immune stimulator to polysaccharide, but ...
Wook-Jin Park +5 more
doaj +1 more source
Safety and immunogenicity of a new glycoengineered vaccine against Acinetobacter baumannii in mice
Microbial Biotechnology, 2022 Summary Acinetobacter baumannii poses a serious threat to human health, mainly because of its widespread distribution and severe drug resistance. However, no licensed vaccines exist for this pathogen. In this study, we created a conjugate vaccine against
Xin Li +9 more
doaj +1 more source
npj Vaccines, 2023 An effective HIV-1 vaccine remains a critical unmet need for ending the AIDS epidemic. Vaccine trials conducted to date have suggested the need to increase the durability and functionality of vaccine-elicited antibodies to improve efficacy.
Danielle Nettere +20 more
doaj +1 more source
On the mechanisms of conjugate vaccines [PDF]
Proceedings of the National Academy of Sciences, 2018 During the last three decades, the development and commercialization of conjugate vaccines against Haemophilus influenzae type b (Hib), pneumococcus, and serogroups C, A, W, and Y of meningococcus contributed to the virtual elimination of bacterial meningitis caused by the bacteria included in the vaccines and to the prevention of diseases that used to
Rino Rappuoli +2 more
openaire +2 more sources
Vaccines against Meningococcal Diseases
Microorganisms, 2020 Neisseria meningitidis is the main cause of meningitis and sepsis, potentially life-threatening conditions. Thanks to advancements in vaccine development, vaccines are now available for five out of six meningococcal disease-causing serogroups (A, B, C, W,
Mariagrazia Pizza +2 more
doaj +1 more source
Vaccine hesitancy and receipt of mandatory and optional pediatric vaccines in Shanghai, China
Human Vaccines & Immunotherapeutics, 2022 Given increased global concern about vaccine hesitancy, this study estimates coverage of mandatory vs non-mandatory vaccines in children, and assesses whether vaccine hesitancy among young parents relates to their childʻs eventual vaccination status in ...
Mengdi Ji +3 more
doaj +1 more source
BMC Immunology, 2018 Background The Haemophilus influenzae type b (Hib) conjugate vaccine has been widely used in children to prevent invasive Hib disease because of its strong immunogenicity and antibody response induction relative to the capsular polysaccharide (CPS ...
Jing Tang +12 more
doaj +1 more source
Long Term Impact of Conjugate Vaccines on Haemophilus influenzae Meningitis: Narrative Review
Microorganisms, 2021 H. influenzae serotype b (Hib) used to be the commonest cause of bacterial meningitis in young children. The widespread use of Hib conjugate vaccine has profoundly altered the epidemiology of H. influenzae meningitis.
Mary Paulina Elizabeth Slack
doaj +1 more source